Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) generates news at the intersection of oncology drug development and artificial intelligence–driven molecular discovery. Public updates highlight the company’s efforts to improve outcomes for cancer patients treated with radiation therapy, as well as its ownership and deployment of the Molecule.ai platform, a pharmaceutical software AI-driven system for molecular discovery and early-stage drug development.
Recent news releases describe several key themes. Shuttle Pharma has reported on its historical Phase II clinical trial of Ropidoxuridine (IPdR) in glioblastoma patients undergoing radiation therapy, including enrollment progress and tolerability data, and later on its decision to discontinue those clinical trials and initiate winddown activities in coordination with its contract research organization and clinical sites. These items provide context on the evolution of the company’s oncology pipeline and its strategic reassessment of clinical programs.
Another major news focus is the acquisition and integration of Molecule.ai. Press releases and 8-K filings detail a binding term sheet, asset purchase agreement and closing of the transaction under which a Shuttle Pharma subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Coverage explains how the platform supports molecular property prediction, drug-target interaction modeling, cross-property evaluation and structured reasoning, and how Shuttle Pharma aims to use these capabilities to augment its drug discovery and development activities.
News items also address capital markets and regulatory developments, such as a private placement involving a pre-funded warrant, related S-1 and S-1/A registration statements for resale of the underlying shares, and communications regarding Nasdaq listing requirements and a reverse stock split undertaken as part of a compliance initiative. Together, these disclosures offer investors and observers a view into SHPH’s scientific programs, AI platform strategy, financing transactions and listing status.
For readers following SHPH news, the company’s updates provide ongoing insight into its transition from a radiation-sensitizer–focused clinical-stage pharmaceutical profile toward a combined biotechnology and AI-driven molecular discovery business model.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 2:30 PM Pacific Time. Dr. Anatoly Dritschilo, Chairman and Chief Scientific Officer, will present updates on two key initiatives:
1. The ongoing Phase 2 trial of Ropidoxuridine and radiation therapy for glioblastoma patients
2. Developments at Shuttle Diagnostics subsidiary, focusing on pretreatment diagnostic blood tests and imaging agents for prostate cancer patients
The presentation will take place at the Paris Hotel & Casino in Las Vegas, with both in-person and webcast attendance options. The company, founded in 2012 by Georgetown University Medical Center faculty, focuses on improving outcomes for cancer patients through radiation therapy enhancement, developing radiation sensitizers to increase cure rates and improve survival rates.
Shuttle Pharmaceuticals (NASDAQ: SHPH) has filed a provisional patent application with the USPTO for 'PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.' The company is developing pretreatment diagnostic blood tests for prostate cancer through its Diagnostics subsidiary.
The patent filing involves collaboration with Dr. Alan Kozikowski, whose previous research contributed to Pylarify and Pluvitco. The technology focuses on developing theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for targeted therapy delivery.
According to market data, the Global PSMA PET Imaging Market reached $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030. Pluvitco, a targeted radiopharmaceutical treatment, has a predicted market size of $2 billion.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has successfully closed its previously announced underwritten public offering, raising $5.75 million in gross proceeds through the sale of 19,166,667 shares of common stock at $0.30 per share.
The company plans to utilize the net proceeds to fund its Phase II clinical trial for its lead product candidate, marketing and advertising services, and working capital. The offering was conducted on a firm commitment basis with WestPark Capital acting as the Sole Book-Runner.
Shuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty members, focuses on developing radiation sensitizers to improve outcomes for cancer patients treated with radiation therapy (RT). Their mission aims to enhance cancer cure rates while limiting radiation side effects when used as primary treatment or in combination with other therapies.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced the pricing of a $5.75 million underwritten public offering, consisting of 19,166,667 shares of common stock at $0.30 per share. The offering, expected to close on March 13, 2025, is being conducted on a firm commitment basis with WestPark Capital as the Sole Book-Runner.
The net proceeds will fund three key initiatives:
- Phase II clinical trial for lead product candidate
- Marketing and advertising services
- Working capital and general corporate purposes
Shuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty, focuses on improving outcomes for cancer patients treated with radiation therapy by developing radiation sensitizers to enhance treatment effectiveness while limiting side effects.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance the company's capital markets and business capabilities. Dr. Anatoly Dritschilo will continue as Chairman of the Board and Co-CEO, focusing on scientific and clinical trial activities.
Cooper brings over 27 years of management and finance experience across various industries. He currently serves as President, CEO, and Founder of First Towers & Fiber Corp since 2017. Previously, he was President and CEO of Aroway Energy (2010-2017) and worked as a Corporate Consultant (1998-2010), raising over $100 million in debt and equity for clients.
The new Co-CEO structure aims to enable parallel execution of R&D, regulatory, and general business operations, with a focus on advancing the company's Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment and the development of their Diagnostics subsidiary.
Shuttle Pharmaceuticals (NASDAQ: SHPH) has provided a corporate update for 2024, highlighting significant progress in its cancer treatment programs. The company reported 40% enrollment completion in the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with 16 out of 40 initial patients enrolled and 8 patients completing all seven cycles.
The trial is being conducted at several prestigious cancer centers including Georgetown University Medical Center and UNC Medical Center. Additionally, Shuttle Pharma's Diagnostics subsidiary entered a research agreement with UCSF to develop a PSMA ligand for cancer diagnosis and therapy.
The company secured additional funding, including a $237,500 investment from CEO Dr. Anatoly Dritschilo. The company's focus remains on developing radiation sensitizers to enhance cancer treatment outcomes and advancing diagnostic tools for predicting radiation therapy success, particularly in prostate cancer treatment.
Shuttle Pharmaceuticals Holdings (SHPH) has reached 25% enrollment in the initial randomized portion of its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial design involves randomizing 40 patients into two dose levels: 1,200 mg/day and 960 mg/day, followed by enrolling 14 additional patients at the optimal dose.
The trial focuses on patients with IDH wild-type, methylation negative glioblastoma, where currently less than half survive beyond 12 months after diagnosis. The study is being conducted at six nationally recognized cancer centers. Ropidoxuridine, Shuttle Pharma's lead radiation sensitizer candidate, has received FDA Orphan Drug Designation.
The company aims to serve an estimated 400,000 US patients treated with radiation therapy for curative purposes annually, with this market expected to grow by 22% over the next five years.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced its participation in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025. CEO Anatoly Dritschilo, M.D., will lead a webcasted fireside chat at 3:30 p.m. Eastern time.
During the virtual event, Dr. Dritschilo will outline the company's 2025 plans, focusing on their Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial is currently enrolling patients at six nationally recognized cancer centers, targeting IDH wild-type, methylation negative glioblastoma.
The discussion will also cover developments in the Shuttle Diagnostics subsidiary, particularly the PC-RAD test for predicting radiation therapy outcomes in prostate cancer patients, and their work on a PSMA ligand as a potential theranostic molecule.
Shuttle Pharmaceuticals Holdings (SHPH) has entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of its PSMA-B ligand for prostate cancer diagnosis and treatment. The research will focus on developing the molecule as a potential diagnostic and therapeutic (theranostic) tool.
UCSF researchers, led by Dr. Robert Flavell, will develop radiosynthetic methods for producing [18F]FPA-ACUPA probe, investigate cellular binding properties, and explore diagnostic potential across various prostate cancer phenotypes. The global PSMA PET Imaging Market reached $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030.
Shuttle Pharmaceuticals Holdings (SHPH) announced the enrollment and dosing of its first patient at UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for glioblastoma treatment. The trial, conducted across six cancer centers, will initially include 40 patients randomized into two doses (20 @ 1,200 mg/day and 20 @ 960 mg/day), followed by an additional 14 patients at the optimal dose. The study targets IDH wild-type, methylation negative glioblastoma patients, who currently have treatment options with radiation therapy. The company previously received FDA Orphan Drug Designation for Ropidoxuridine.